Unlabelled: Amnestic Mild Cognitive Impairment (MCI) is one of the cognitive profiles of aging.
Objective: In this study, Memory Specificity Training (MEST) was used as cognitive training in patients with amnestic MCI to understand the effectiveness of the intervention on memory dimensions.
Methods: Twenty patients that met the criteria for amnestic MCI were selected and randomly assigned to experimental (n=10) or control (n=10) groups. The experimental group received five sessions of training on memory specificity while the participants in the control group took part in two general placebo sessions. Participants were assessed before, immediately after, and three months after, the treatment using the Autobiographical Memory Test, the Prospective and Retrospective Memory Questionnaire, the Wechsler Memory Scale, and the Hospital Anxiety and Depression Scale. Analysis of variance was used to analyze the data.
Results: Results from both post-test and follow-up treatment indicated that MEST improves working and prospective memory (p<0.05).
Conclusion: These findings support the effectiveness of MEST for MCI patients as a viable cognitive intervention. Also, the findings have implications for the role of brain plasticity in the effectiveness of this intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674669 | PMC |
| http://dx.doi.org/10.1590/1980-57642016dn11-030007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Antigen- and Vector-Specific Immune Responses of a Recombinant Pichinde Virus-Based Vaccine Expressing the Lymphocytic Choriomeningitis Virus Nucleoprotein.
Vaccines (Basel)
December 2024
Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN 55108, USA.
Background: Live viral vector-based vaccines are known to elicit strong immune responses, but their use can be limited by anti-vector immunity. Here, we analyzed the immunological responses of a live-attenuated recombinant Pichinde virus (PICV) vector platform (rP18tri).
Methods: To evaluate anti-PICV immunity in the development of vaccine antigen-specific immune responses, we generated a rP18tri-based vaccine expressing the lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP) and administered four doses of this rP18tri-NPLCMV vaccine to mice.
Receptor Binding Domain-Specific B Cell Memory Responses Among Individuals Vaccinated Against SARS-CoV-2.
Vaccines (Basel)
December 2024
BRIC-Translational Health Science and Technology Institute, Faridabad 21001, India.
: The COVID-19 pandemic prompted unprecedented vaccine development efforts against SARS-CoV-2. India, which was one of the countries most impacted by COVID-19, developed its indigenous vaccine in addition to utilizing the ones developed by other countries. While antibody levels and neutralizing antibody titres are considered initial correlates of immune protection, long-term protection from the pathogen relies on memory B and T cells and their recall responses.
View Article and Find Full Text PDFThe Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice.
Vaccines (Basel)
December 2024
Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Plague, caused by , poses a public health threat not only due to sporadic outbreaks across the globe but also due to its potential as a biothreat agent. Ironically, among the seven deadliest pandemics in global history, three were caused by . Pneumonic plague, the more contagious and severe form of the disease, is difficult to contain, requiring either prophylactic antibiotic treatment or vaccination.
View Article and Find Full Text PDFRSV Vaccine with Nanoparticle-Based Poly-Sorbitol Transporter (PST) Adjuvant Improves Respiratory Protection Against RSV Through Inducing Both Systemic and Mucosal Humoral Immunity.
Vaccines (Basel)
November 2024
Department of Systems Biotechnology, Chung-Ang University, Anseong 17456, Republic of Korea.
Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (T) cells and tissue-resident memory B (B) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses.
View Article and Find Full Text PDFChallenges and New Directions in Therapeutic Cancer Vaccine Development.
Vaccines (Basel)
November 2024
Laboratory of Drug Discovery from Natural Resources and Industrialization, School of Pharmacy, Macau University of Science and Technology, Macau 999078, China.
Tumor vaccine is a promising immunotherapy for solid tumors. Therapeutic tumor vaccines aim at inducing tumor regression, establishing durable antitumor memory, and avoiding non-specific or adverse reactions. However, tumor-induced immune suppression and immune resistance pose challenges to achieving this goal.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!